SCHEMBL485159

SCHEMBL485159

ClCc1nnc(-c2ccccc2)o1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 1.00
LMNA P02545 1/20 1.00
NOTUM Q6P988 4/20 0.67
RAB9A P51151 8/20 0.65
NPC1 O15118 6/20 0.65
SMN1; SMN2 Q16637 5/20 0.65
HPGD P15428 1/20 0.65
TSHR P16473 1/20 0.65
GPR55 Q9Y2T6 1/20 0.65
POLB P06746 2/20 0.59
KCNH2 Q12809 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.55
MAPT P10636 3/20 0.55
KDM4E B2RXH2 1/20 0.55
KMT2A Q03164 2/20 0.53
ATM Q13315 1/20 0.53
ATAD2 Q6PL18 1/20 0.52
HDAC8 Q9BY41 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28295593 0.85 ALDH1A1 (0.73) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL19343385 0.83 RAB9A (0.81) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL2640766 0.82 ALDH1A1 (0.70) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL25916050 0.81 ALDH1A1 (0.68) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL2640701 0.81 ALDH1A1 (0.68) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL5124689 0.81 ALDH1A1 (0.68) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL3423891 0.81 TSHR (0.73) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL5117429 0.81 ALDH1A1 (0.68) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL30566753 0.80 ALDH1A1 (0.67) ALDH1A1LMNANOTUMRAB9ANPC1
SCHEMBL16963153 0.80 ALDH1A1 (0.67) ALDH1A1LMNANOTUMRAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107129518-A The triterpenoid saponin analog derivative of one class nitrogen heterocyclic ring structure and its synthetic method and application 延边大学 2017-09-05 CN claimed
CN-119504633-A Peach girder phenol derivative containing 1,3, 4-oxa/thiadiazole, preparation method and application thereof 扬州大学 2025-02-25 CN disclosed
CN-111548319-B 1, 1-dicyanooxime ether compound and application thereof 沈阳化工大学 2024-03-08 CN disclosed
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds IDEAYA BIOSCIENCES, INC. (US) 2023-02-21 US disclosed
US-20230045960-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2023-02-16 US disclosed
US-11530210-B2 Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators JANSSEN PHARMACEUTICA NV (BE) 2022-12-20 US disclosed
US-20220274984-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-09-01 US disclosed
EP-3982958-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS Janssen Pharmaceutica NV (BE) 2022-04-20 EP disclosed
CN-114007610-A Substituted heteroaromatic pyrazolopyridines and their use as modulators of the GLUN2B receptor 詹森药业有限公司 2022-02-01 CN disclosed
US-20210017169-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-01-21 US disclosed
US-20020032189-A1 For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders THE UNIVERSITY OF TOKYO (JP) 2002-03-14 US disclosed
US-6310107-B1 (+)-6-(4-BIPHENYLYL)METHOXY-2-(2-(N,N-DIMETHYLAMINO)ETHYL)TETR ALIN, OR A SALT IS USEFUL FOR INHIBITING PRODUCTION AND/OR SECRETION OF AMYLOID-BETA PROTEIN TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2001-10-30 US disclosed
EP-0971878-A1 AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS Takeda Pharmaceutical Company Limited (JP) 2000-01-19 EP disclosed
WO-1998038156-A1 AMINE COMPOUNDS, THEIR PRODUCTION AND USE AS AMYLOID-BETA PRODUCTION INHIBITORS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 1998-09-03 WO disclosed
EP-0222576-B1 HETEROCYCLIC OXOPHTHALAZINYL ACETIC ACIDS PFIZER INC. (US) 1992-03-18 EP disclosed
US-4748280-A Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6) PFIZER INC. (US) 1988-05-31 US disclosed
US-4723010-A Process for preparing chloromethyl thiazoles or oxazoles, and intermediates for use therein PFIZER INC. (US) 1988-02-02 US disclosed
EP-0222576-A2 Heterocyclic oxophthalazinyl acetic acids PFIZER INC. (US) 1987-05-20 EP disclosed
US-4104468-A 1,3,4-Oxadiazolyl-(2)-vinyl stilbene optical brighteners SANDOZ LTD. (CH) 1978-08-01 US disclosed
US-3947410-A OPTICAL BRIGHTENERS CIBA-GEIGY CORPORATION (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045960-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885NOTUM 4680/4885
US-20220274984-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885NOTUM 4680/4885
US-20210017169-A1 SUBSTITUTED HETEROAROMATIC PYRAZOLO-PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885NOTUM 4680/4885
US-20020032189-A1 For therapy and prophylaxis of neurodegenerative diseases such as Alzheimer's disease, Down's syndrome, Parkinson's disease, Creutzfeldt-Jacob disease, amyotrophic sclerosis on lateral fasciculus, multiple sclerosis, and neurological disorders PARK7, PSEN1, PRNP ALDH1A1 4024/4885LMNA 503/4885NOTUM 4118/4885
US-11530210-B2 Substituted heteroaromatic pyrazolo-pyridines and their use as GLUN2B receptor modulators GRIN2B, GRIN2A, GRIN2C ALDH1A1 2477/4885LMNA 4111/4885NOTUM 4680/4885
US-11584755-B2 Dihydrothieno[3,2-b]pyridine compounds DHFR, CYC1, CYCS ALDH1A1 700/4885LMNA 2628/4885NOTUM 4542/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.